1
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: MAPK/ERK KINASE INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY, TAKEDA SAN DIEGO, May 27, 2010: US20100130518-A1

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of usin ...


2
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: Mapk/erk kinase inhibitors. Takeda San Diego, October 16, 2008: US20080255160-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


3
Toufike Kanouni
MarK Adams, Qing Dong, Toufike Kanouni, Stephen W Kaldor, Nicholas Scorah, Michael B Wallace: Mapk/erk kinase inhibitors. Takeda Pharmaceutical Company, Takeda San Diego, May 14, 2009: US20090124595-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


4
Jerome C Bressi, Sheldon X Cao, Jeffrey A Stafford, Phong H Vu: Histone deacetylase inhibitors. Takeda San Diego, Takeda San Diego, June 28, 2007: US20070149495-A1

Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained C1-12 alkyl, C2-12 aminoalkyl or C2-12 oxaalkyl, and a substitut ...


5
Jerome C Bressi, Jason W Brown, Anthony R Gangloff, Andrew J Jennings, Stephen W Kaldor, Robert J Skene, Jeffrey A Stafford, Phong H Vu: Histone deacetylase inhibitors. Takeda San Diego, July 26, 2007: US20070173527-A1

Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.


6
Jason W Brown, Sanjib Das, Qing Dong, Xianchang Gong, Stephen W Kaldor, Yan Liu, Bheema R Paraselli, Nicholas Scorah, Jeffrey A Stafford, Michael B Wallace: Kinase inhibitors. Takeda San Diego, May 24, 2007: US20070117816-A1

Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.


7
Jerome C Bressi, Jason W Brown, Anthony R Gangloff, Jeffrey A Stafford, Phong H Vu: Histone deacetylase inhibitors. Takeda San Diego, November 16, 2006: US20060258694-A1

Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.


8
Ronald J Christopher, Paul Covington: Administration of dipeptidyl peptidase inhibitors. Takeda San Diego, March 15, 2007: US20070060528-A1

Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as ...


9
Ronald J Christopher, Paul Covington: Administration of dipeptidyl peptidase inhibitors. Takeda San Diego, March 15, 2007: US20070060529-A1

Pharmaceutical compositions comprising 2-[[2-[(3R)-3-Amino-piperidinyl)-5-fluoro-6-oxo-6H-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the ...


10
Ronald J Christopher, Paul Covington: Administration of dipeptidyl peptidase inhibitors. Takeda San Diego, March 15, 2007: US20070060530-A1

Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well ...